Faculty
Ma.jpg

Cynthia X. Ma, MD, PhD

Professor
Department of Medicine
Oncology Division
Medical Oncology

Clinical Interests

  • Breast cancer

Research Interests

  • Pharmacogenomics of anticancer agents
  • Predictive biomarkers
  • Developmental therapeutics

Contact

  • 314-747-3096 (tel)
  • 314-362-7086 (fax)
  • Room 3311, Couch Biomedical Research Building (office)
  • Division of Oncology
    Campus Box 8076
    Washington University Medical School
    660 South Euclid Avenue
    St. Louis, MO 63110

Invited Publications

  • Neoadjuvant Endocrine Therapy: Who Benefits Most?
    Grossman J, Ma C, Aft R
    Surg Oncol Clin N Am 2018 Jan;27(1):121-140
  • The Role of Neratinib in HER2-Driven Breast Cancer
    Cherian MA, Ma CX
    Future Oncol 2017 Jun 30; [Epub ahead of print]
  • New Insights in Estrogen Receptor Biology and Implication for Treatment
    Oza A, Ma CX
    Current Breast Cancer Reports - Springer (9-1), 2017, Feb 14. E pub
  • Beyond Genomics: Biologic Insights From the CPTAC Proteogenomic Analysis of Breast Cancer
    Rajput S, Ma CX
    Translational Cancer Research 2016 Oct;5(Suppl 4):S713-S715
  • Treating and Managing Future Risk in Women With Hereditary Breast Cancer
    Ma CX
    Cancer News in Context, July 13, 2016
  • Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer
    Hernandez-Aya LF, Ma CX
    Breast Diseases: A Year Book Quarterly. 2016
  • Chemotherapy Principles of Managing Stage IV Breast Cancer in the United States
    Hernandez-Aya LF, Ma CX
    Chin Clin Oncol 2016 Jun;5(3):42
  • Prognostic and Predictive Biomarkers of Endocrine Responsiveness for Estrogen Receptor Positive Breast Cancer
    Ma CX, Bose R, Ellis MJ
    Adv Exp Med Biol 2016;882:125-54
  • Improving Response to Hormone Therapy in Breast Cancer: New Targets, New Therapeutic Options
    Rugo HS, Vidula N, Ma C
    Am Soc Clin Oncol Educ Book 2016;35:e40-54
  • Breast Cancer, Chapter 24
    Ademuyiwa F, Bose R, Ma CX
    In: DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology Review, 4e
  • Neratinib in Early-Stage HER2-Positive Breast Cancer
    Cherian MA, Ma CX
    Breast Diseases: A Year Book Quarterly. 2015 December
  • DCIS: Time to Change Our Standard of Care?
    Ma CX
    Oncology Times 2015 August
  • Revisiting the Estrogen Receptor Pathway and Its Role in Endocrine Therapy for Postmenopausal Women With Estrogen Receptor-Positive Metastatic Breast Cancer
    Nagaraj G, Ma C
    Breast Cancer Res Treat 2015 Apr;150(2):231-42
  • The PI3K Pathway as a Therapeutic Target in Breast Cancer
    Ma CX
    American Journal of Hematology/Oncology. 2015 March
  • Mechanisms of Aromatase Inhibitor Resistance
    Ma CX, Reinert T, Chmielewska I, Ellis MJ
    Nat Rev Cancer 2015 Apr 24;15(5):261-75
  • Key Breast Cancer Takeaways From ASCO 2015
    Ma CX
    Oncology Times 2015 June 29
  • Key Breast Cancer Takeaways From Asco 2014
    Ma CX
    Oncology Times 2014 June 29
  • Chapter 14: Breast Cancer
    Ademuyiwa F, Suresh R, Ellis MJ, Ma CX
    In: Washington Manual of Oncology 4th Edition, Lippincott Williams & Wilkens 2014
  • Metastatic Breast Cancer: Best Practices Based on Cancer Subtypes
    Ma CX
    Young Women’s Breast Cancer Program in St. Louis Magazine. 2014
  • Best Breast Cancer Research 2013
    Ma CX
    Oncology Times 2014 Jan 24
  • The Cancer Genome Atlas: Clinical Applications for Breast Cancer
    Ma CX, Ellis MJ
    Oncology (Williston Park) 2013 Dec;27(12):1263-9, 1274-9
  • Incorporating Genomics Into Breast Cancer Clinical Trials and Care
    Tabchy A, Ma CX, Bose R, Ellis MJ
    Clin Cancer Res 2013 Dec 1;19(23):6371-9
  • Neoadjuvant Therapy in Operable Breast Cancer: Application to Triple Negative Breast Cancer
    Ademuyiwa FO, Ellis MJ, Ma CX
    J Oncol 2013;2013:219869
  • Chapter 19: Genomic Events in Breast Cancer Progression
    Goncalves R, Cakar B, Bose R, Ma CX, Ellis MJ
    In: Disease of the Breast, 5th Edition
  • Targeted Therapy for Breast Cancer
    Mohamed A, Krajewski K, Cakar B, Ma CX
    Am J Pathol 2013 Oct;183(4):1096-112
  • PI3K Inhibitors in Breast Cancer Treatment
    Pacheco JM, Ma CX
    The International Journal of Targeted Therapies in Cancer 2013 May 7
  • Biology of Breast Cancer - Better Therapy Promised for Triple Negative Breast Cancer
    Ma CX
    Oncology Times 2013 Jan 6
  • Mammalian Target of Rapamycin Inhibitors in Breast Cancer Therapy CML
    Ezewuiro O, Ma CX, Fleming GF
    Breast Cancer 2012;24(4):117–30
  • The Natural History of Hormone Receptor-Positive Breast Cancer: Attempting to Decipher an Intriguing Concept
    Nagaraj G, Ellis MJ, Ma CX
    Oncology (Williston Park) 2012 Aug;26(8):696-7, 700
  • Endocrine Resistance in Breast Cancer: Molecular Pathways and Rational Development of Targeted Therapies
    Roop RP, Ma CX
    Future Oncol 2012 Mar;8(3):273-92
  • Use of Neoadjuvant Data to Design Adjuvant Endocrine Therapy Trials for Breast Cancer
    Goncalves R, Ma C, Luo J, Suman V, Ellis MJ
    Nat Rev Clin Oncol 2012 Feb 28;9(4):223-9
  • Molecular Basis of Triple Negative Breast Cancer and Implications for Therapy
    Peddi PF, Ellis MJ, Ma C
    Int J Breast Cancer 2012;2012:217185
  • PARP Inhibitors and Their Evolving Role in Breast Cancer
    Roop RP, Ma CX, Ellis MJ
    Oncology (Williston Park) 2011 Oct;25(11):1033-4
  • Estrogen and Progesterone Receptors in Breast Cancer
    Ma CX
    Clin Adv Hematol Oncol 2011 May;9(5):385-6
  • Systemic Therapy for Metastatic Breast Cancer: Endocrine Therapy (Online Chapter)
    Ellis M, Hayes D, Naughton M, Ma CX
    UpToDate 19.2 2011
  • Importance of PI3-Kinase Pathway in Response/Resistance to Aromatase Inhibitors
    Ma CX, Crowder RJ, Ellis MJ
    Steroids 2011 Jul;76(8):750-2
  • Death by Releasing the Breaks: CHK1 Inhibitors as Cancer Therapeutics
    Ma CX, Janetka JW, Piwnica-Worms H
    Trends Mol Med 2011 Feb;17(2):88-96
  • Optimal Selection of Adjuvant Chemotherapy in Patients With Breast Cancer (Chapter)
    Ma CX
    Epocrates 2010
  • Molecular Profiling of Triple Negative Breast Cancer
    Ma CX, Luo J, Ellis MJ
    Breast Dis 2010 Jan 1;32(1):73-84
  • Hedgehog Pathway Inhibitors: Potential Applications in Breast Cancer (Review)
    Chia YH, Ma CX
    Current Breast Cancer Report 2010;3(1):15-23
  • Neoadjuvant Endocrine Therapy in Primary Breast Cancer: Indications and Use as a Research Tool
    Chia YH, Ellis MJ, Ma CX
    Br J Cancer 2010 Sep 7;103(6):759-64
  • Commentary on "Functional Genetic Polymorphisms in the Aromatase Gene CYp19 Vary the Response of Breast Cancer Patients to Neoadjuvant Therapy With Aromatase Inhibitors. Cancer Research 70 (1):319-28"
    Ma CX, Ellis MJ
    Breast Diseases: A Year Book Quarterly 2010;21(3):266-7
  • Neoadjuvant Endocrine Therapy for Breast Cancer
    Chawla JS, Ma CX, Ellis MJ
    Surg Oncol Clin N Am 2010 Jul;19(3):627-638
  • Updates on Adjuvant Trastuzumab Therapy for Breast Cancer
    Ma CX
    China Medical Tribute B4-B5 2010 March 18; B4-B5
  • Commentary on "Letrozole Therapy Alone or in Sequence With Tamoxifen in Women With Breast Cancer. N Engl J Med 361(8):766-76"
    Chia YH, Ma CX, Ellis MJ
    Breast Diseases: A Year Book Quarterly 2010;21(2):168-9
  • Neoadjuvant Endocrine Therapy for Breast Cancer
    Chia YH, Ma CX, Ellis MJ
    Breast Diseases: A Year Book Quarterly 2009;20(4):355-7
  • Commentary on "Cohort Study Examining Tamoxifen Adherence and Its Relationship to Mortality in Women With Breast Cancer. Br J Cancer 99:1763-8"
    Chia YH, Ma CX
    Breast Diseases: A Year Book Quarterly 2009;20(3):327-8
  • Commentary on "Double-Blind, Randomized Placebo Controlled Trial of Fulvestrant Compared With Exemestane After Prior Nonsteroidal Aromatase Inhibitor Therapy in Postmenopausal Women With Hormone Receptor–positive, Advanced Breast Cancer: Results From EFECT. J Clin Oncol 26:1664-70"
    Chia YH, Ma CX
    Breast Diseases: A Year Book Quarterly 2009;20(1):94-5
  • An Update on Adjuvant Therapy With Trastuzumab, Part 3
    Chia YH, Ma CX
    E-Updates in HER2 Targeting in Breast Cancer 2009; 3
  • An Update on the Use of Lapatinib, Part 3
    Ma CX, Chia YH
    E-Updates in HER2 Targeting in Breast Cancer 2009; 3
  • Predicting Endocrine Therapy Responsiveness in Breast Cancer
    Ma CX, Sanchez CG, Ellis MJ
    Oncology (Williston Park) 2009 Feb;23(2):133-42
  • Letrozole in the Neoadjuvant Setting: The P024 Trial
    Ellis MJ, Ma C
    Breast Cancer Res Treat 2007;105 Suppl 1:33-43
  • Femara and the Future: Tailoring Treatment and Combination Therapies With Femara
    Ellis M, Ma C
    Breast Cancer Res Treat 2007;105 Suppl 1:105-15
  • Commentary on "A Meta-Analysis on the Interaction Between HER-2 Expression and Response to Endocrine Treatment in Advanced Breast Cancer, Clinical Cancer Research 11(13):4741-8"
    Ma CX, Ellis MJ
    Breast Diseases, A Year Book Quarterly 2006;17(3):282-3
  • Commentary on "Can Molecular Markers Predict When to Implement Treatment with Aromatase Inhibitors in Invasive Breast Cancer? Clinical Cancer Research 11(13):4835-42"
    Ma CX, Ellis MJ
    Breast Diseases, A Year Book Quarterly 2006:17(3):286-7
  • Neoadjuvant Endocrine Therapy for Locally Advanced Breast Cancer
    Ma CX, Ellis MJ
    Semin Oncol 2006 Dec;33(6):650-6
  • Endocrine Therapy Resistance: Molecular Predictive Models and Mechanism-Based Solutions
    Ma CX, Ellis MJ
    Translating advances in hormonal therapies for breast cancer into clinical practice: a continuing education monograph for oncology professionals by Meniscus, Aug 2006: pp 25-34